Protagonist Therapeutics, Inc.
$104.42
▼
-1.39%
2026-04-22 10:12:13
www.protagonist-inc.com
NGM: PTGX
Explore Protagonist Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$6.74 B
Current Price
$104.42
52W High / Low
$107.84 / $41.28
Stock P/E
—
Book Value
$9.82
Dividend Yield
—
ROCE
-25.39%
ROE
-20.18%
Face Value
—
EPS
$-2.05
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
132
Beta
2.11
Debt / Equity
1.68
Current Ratio
12.71
Quick Ratio
12.71
Forward P/E
-227.58
Price / Sales
137.03
Enterprise Value
$5.75 B
EV / EBITDA
-36.65
EV / Revenue
124.92
Rating
Strong Buy
Target Price
$112.42
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Erasca, Inc. | $21.71 | — | $5.91 B | — | -35.74% | -33.27% | $19.78 / $1.06 | $1.14 |
| 2. | Lunai Bioworks Inc. | $0.34 | — | $12.33 M | — | 88.63% | -3.66% | $5.5 / $0.15 | $-0.56 |
| 3. | OS Therapies Incorporated | $1.38 | — | $58.43 M | — | 582.87% | 614.26% | $2.57 / $1.15 | $-0.16 |
| 4. | Cabaletta Bio, Inc. | $3.31 | — | $382.95 M | — | -149.87% | -1.27% | $3.78 / $1.06 | $1.11 |
| 5. | TuHURA Biosciences, Inc. | $2.83 | — | $179.93 M | 0% | -120.19% | -1.69% | $4.44 / $0.41 | $0.35 |
| 6. | FibroBiologics, Inc. | $1.53 | — | $5.37 M | — | -211.82% | -4.19% | $30.6 / $1.03 | $1.85 |
| 7. | Ernexa Therapeutics Inc. | $0.19 | — | $5.87 M | 0.34% | -342.48% | -6.87% | $4.05 / $0.18 | $0.31 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 7.44 M | 4.71 M | 5.55 M | 28.32 M | 170.64 M | — |
| Operating Profit | -50.35 M | -46.42 M | -42.04 M | -19.31 M | 126.78 M | — |
| Net Profit | -44.38 M | -39.34 M | -34.77 M | -11.65 M | 131.67 M | — |
| EPS in Rs | -0.7 | -0.62 | -0.54 | -0.18 | 2.06 | -0.54 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 46.02 M | 434.43 M | 60 M | 26.58 M |
| Operating Profit | -158.13 M | 252.84 M | -93.65 M | -131.37 M |
| Net Profit | -130.15 M | 275.19 M | -78.95 M | -127.39 M |
| EPS in Rs | -2.04 | 4.31 | -1.24 | -2 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 668.19 M | 744.73 M | 357.95 M | 247.93 M |
| Total Liabilities | 53.48 M | 69.43 M | 21.27 M | 32.32 M |
| Equity | 614.71 M | 675.29 M | 336.68 M | 215.61 M |
| Current Assets | 577.57 M | 591.64 M | 355.58 M | 243.08 M |
| Current Liabilities | 45.44 M | 47.4 M | 21.27 M | 31.18 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 57.67 M | 184.15 M | -70.24 M | -108.14 M |
| Investing CF | -49.33 M | -299.48 M | -39.26 M | 91.47 M |
| Financing CF | 22.86 M | 25.85 M | 170.48 M | 18.84 M |
| Free CF | 56.08 M | 182.8 M | -70.84 M | -108.93 M |
| Capex | -1.59 M | -1.35 M | -0.61 M | -0.8 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 624.05% | 125.73% | — | — |
| Earnings Growth % | 448.54% | 38.02% | — | — |
| Profit Margin % | 63.34% | -131.59% | -479.26% | — |
| Operating Margin % | 58.2% | -156.09% | -494.24% | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | 58.39% | -154.46% | -490.35% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.